Axsome Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300EXGR0XLRJEIB95 - ISIN
US05464T1043 (AXSM )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€424.74M - Gross margin
91.5% - EBIT
-€196.43M - EBIT margin
-46.2% - Net income
-€211.84M - Net margin
-49.9%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Saad Mark E | N/A |
|
|
|
|
| JEFFS ROGER | N/A |
|
|
|
|
| JEFFS ROGER | N/A |
|
|
|
|
| JEFFS ROGER | N/A |
|
|
|
|
Earnings Calls
Latest earnings call: May 6, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |